1. Home
  2. HYPR vs BDTX Comparison

HYPR vs BDTX Comparison

Compare HYPR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$0.96

Market Cap

94.7M

Sector

Health Care

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.79

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
BDTX
Founded
2014
2014
Country
United States
United States
Employees
102
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.7M
171.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
HYPR
BDTX
Price
$0.96
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
7
Target Price
$1.59
$9.67
AVG Volume (30 Days)
1.7M
1.6M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
23.21
130.71
EPS
N/A
N/A
Revenue
$13,563,000.00
N/A
Revenue This Year
$50.75
N/A
Revenue Next Year
$29.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.22
N/A
52 Week Low
$0.85
$1.60
52 Week High
$2.22
$4.94

Technical Indicators

Market Signals
Indicator
HYPR
BDTX
Relative Strength Index (RSI) 32.72 42.31
Support Level $0.88 $1.76
Resistance Level $1.19 $2.26
Average True Range (ATR) 0.07 0.11
MACD -0.01 0.01
Stochastic Oscillator 16.26 6.17

Price Performance

Historical Comparison
HYPR
BDTX

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: